Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 12;15(8):2254.
doi: 10.3390/cancers15082254.

The Onco-Nephrology Field: The Role of Personalized Chemotherapy to Prevent Kidney Damage

Annalisa Noce  1   2 , Giulia Marrone  1 , Manuela Di Lauro  1 , Anna Paola Mitterhofer  1   2 , Maria Josè Ceravolo  2 , Nicola Di Daniele  1   3 , Guglielmo Manenti  4 , Antonino De Lorenzo  5
Affiliations
Review

The Onco-Nephrology Field: The Role of Personalized Chemotherapy to Prevent Kidney Damage

Annalisa Noce et al. Cancers (Basel). .

Abstract

In recent years, the onco-nephrology field has acquired a relevant role in internal medicine due to the growing number of cases of renal dysfunction that have been observed in cancer patients. This clinical complication can be induced by the tumor itself (for example, due to obstructive phenomena affecting the excretory tract or by neoplastic dissemination) or by chemotherapy, as it is potentially nephrotoxic. Kidney damage can manifest as acute kidney injury or represent a worsening of pre-existing chronic kidney disease. In cancer patients, physicians should try to set preventive strategies to safeguard the renal function, avoiding the concomitant use of nephrotoxic drugs, personalizing the dose of chemotherapy according to the glomerular filtration rate (GFR) and using an appropriate hydration therapy in combination with nephroprotective compounds. To prevent renal dysfunction, a new possible tool useful in the field of onco-nephrology would be the development of a personalized algorithm for the patient based on body composition parameters, gender, nutritional status, GFR and genetic polymorphisms.

Keywords: acute kidney injury; chemotherapeutic drugs; chronic kidney disease; predictive algorithm; renal insufficiency.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The new medicine field of onco-nephrology.
See this image and copyright information in PMC

References

    1. Fofi C., Festuccia F. Onconephrology: A New Challenge for the Nephrologist. Contrib. Nephrol. 2021;199:91–105. doi: 10.1159/000517695. - DOI - PubMed
    1. Rosner M.H., Jhaveri K.D., McMahon B.A., Perazella M.A. Onconephrology: The intersections between the kidney and cancer. CA Cancer J. Clin. 2021;71:47–77. doi: 10.3322/caac.21636. - DOI - PubMed
    1. de Francisco A.L.M., Macia M., Alonso F., Garcia P., Gutierrez E., Quintana L.F., Quiroga B., Torregrosa I. Onco-Nephrology: Cancer, chemotherapy and kidney. Nefrologia (Engl. Ed.) 2019;39:473–481. doi: 10.1016/j.nefroe.2018.10.016. - DOI - PubMed
    1. Launay-Vacher V., Janus N., Deray G. Renal insufficiency and cancer treatments. ESMO Open. 2016;1:e000091. doi: 10.1136/esmoopen-2016-000091. - DOI - PMC - PubMed
    1. Launay-Vacher V., Oudard S., Janus N., Gligorov J., Pourrat X., Rixe O., Morere J.F., Beuzeboc P., Deray G., Renal I., et al. Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: The renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007;110:1376–1384. doi: 10.1002/cncr.22904. - DOI - PubMed

LinkOut - more resources